Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pacific Biosciences (NASDAQ:PACB) and Pacira Pharmaceuticals (NASDAQ:PCRX).
Pacific Biosciences (PACB)
Piper Jaffray analyst William Quirk reiterated a Hold rating on Pacific Biosciences yesterday and set a price target of $3.80. The company’s shares closed yesterday at $3.88.
According to TipRanks.com, Quirk is a 5-star analyst with an average return of 18.3% and a 68.8% success rate. Quirk covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Idexx Laboratories, and Becton Dickinson.
Currently, the analyst consensus on Pacific Biosciences is a Moderate Buy with an average price target of $4.15.
See today’s analyst top recommended stocks >>
Pacira Pharmaceuticals (PCRX)
In a report released yesterday, David Amsellem from Piper Jaffray reiterated a Buy rating on Pacira Pharmaceuticals, with a price target of $48. The company’s shares closed yesterday at $43.
According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -1.6% and a 46.4% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $50.42, a 17.3% upside from current levels. In a report issued on July 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $48 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
